{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:51:28Z","timestamp":1791697888910,"version":"4.3.4"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Veterinary Journal"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.tvjl.2022.105899","type":"journal-article","created":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T01:20:24Z","timestamp":1663982424000},"page":"105899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Management of pituitary pars intermedia dysfunction in practice: A clinical audit"],"prefix":"10.1016","volume":"289","author":[{"given":"N.L.","family":"Steel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.L.","family":"Ireland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.M.","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tvjl.2022.105899_bib1","first-page":"141","article-title":"Freedom of Information Summary. Prascend tablets, pergolide mesylate, for the control of clinical signs associated with pituitary pars intermedia dysfunction (equine Cushing\u2019s disease) in horses. Original New Animal Drug Application","author":"Andrews","year":"2011","journal-title":"NADA"},{"key":"10.1016\/j.tvjl.2022.105899_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.rvsc.2011.05.013","article-title":"Cortisol, adrenocorticotropic hormone, serotonin, adrenaline and noradrenaline serum concentrations in relation to disease and stress in the horse","volume":"93","author":"Ayala","year":"2012","journal-title":"Research in Veterinary Science"},{"key":"10.1016\/j.tvjl.2022.105899_bib3","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/j.2042-3306.2011.00444.x","article-title":"Circannual variation in plasma adrenocorticotropic hormone concentrations in the UK in normal horses and ponies, and those with pituitary pars intermedia dysfunction","volume":"44","author":"Copas","year":"2012","journal-title":"Equine Veterinary Journal"},{"key":"10.1016\/j.tvjl.2022.105899_bib4","first-page":"742","article-title":"Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease)","volume":"16","author":"Donaldson","year":"2002","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2022.105899_bib5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2460\/javma.2004.224.1123","article-title":"Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis","volume":"224","author":"Donaldson","year":"2004","journal-title":"Journal of the American Veterinary Medical Association"},{"key":"10.1016\/j.tvjl.2022.105899_bib6","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/eve.12160","article-title":"Pituitary pars intermedia dysfunction: diagnosis and treatment","volume":"26","author":"Durham","year":"2014","journal-title":"Equine Veterinary Education"},{"key":"10.1016\/j.tvjl.2022.105899_bib7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/evj.13292","article-title":"Clinically and temporally specific diagnostic thresholds for plasma ACTH in the horse","volume":"53","author":"Durham","year":"2021","journal-title":"Equine Veterinary Journal"},{"key":"10.1016\/j.tvjl.2022.105899_bib8","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/eve.12130","article-title":"Current best practice in clinical management of equine endocrine patients","volume":"26","author":"Frank","year":"2014","journal-title":"Equine Veterinary Education"},{"key":"10.1016\/j.tvjl.2022.105899_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/vetr.142","article-title":"Pergolide dosing compliance and factors affecting the laboratory control of equine pituitary pars intermedia dysfunction","author":"Hague","year":"2021","journal-title":"Veterinary Record"},{"key":"10.1016\/j.tvjl.2022.105899_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.tvjl.2018.03.002","article-title":"Epidemiology of pituitary pars intermedia dysfunction: a systematic literature review of clinical presentation, disease prevalence and risk factors","volume":"235","author":"Ireland","year":"2018","journal-title":"The Veterinary Journal"},{"key":"10.1016\/j.tvjl.2022.105899_bib11","first-page":"CD000259","article-title":"Audit and feedback: effects on professional practice and healthcare outcomes","volume":"6","author":"Ivers","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1016\/j.tvjl.2022.105899_bib12","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1111\/jvim.16281","article-title":"Repeatability of a thyrotropin\u2010releasing hormone stimulation test for diagnosis of pituitary pars intermedia dysfunction in mature horses","volume":"35","author":"Kam","year":"2021","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2022.105899_bib13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.2042-3306.2012.00578.x","article-title":"Prevalence, risk factors and clinical signs predictive for equine pituitary pars intermedia dysfunction in aged horses","volume":"45","author":"McGowan","year":"2013","journal-title":"Equine Veterinary Journal"},{"key":"10.1016\/j.tvjl.2022.105899_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/vr.139.2.41","article-title":"Pergolide treatment for Cushing's syndrome in a horse","volume":"139","author":"Mu\u00f1oz","year":"1996","journal-title":"Veterinary Record"},{"key":"10.1016\/j.tvjl.2022.105899_bib15","first-page":"1","article-title":"Principles for best practice in clinical audit","volume":"23\u201327","author":"National Institute for Clinical Excellence","year":"2002","journal-title":"Oxford: Radcliffe Medical Press"},{"key":"10.1016\/j.tvjl.2022.105899_bib16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.2746\/042516402776250333","article-title":"Plasma adrenocorticotropin ACTH concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide","volume":"34","author":"Perkins","year":"2002","journal-title":"Equine Veterinary Journal"},{"key":"10.1016\/j.tvjl.2022.105899_bib17","doi-asserted-by":"crossref","first-page":"598","DOI":"10.21836\/PEM20100416","article-title":"Equine Cushing\u2019s syndrome. The effects of long-term therapy with pergolide","volume":"26","author":"Pongratz","year":"2010","journal-title":"Pferdeheilkunde"},{"key":"10.1016\/j.tvjl.2022.105899_bib18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.1939-1676.2012.00932.x","article-title":"Diagnostic frequency, response to therapy, and long-term prognosis among horses and ponies with pituitary par intermedia dysfunction, 1993-2004","volume":"26","author":"Rohrbach","year":"2012","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2022.105899_bib19","unstructured":"Schott H.C. 2013. Medical management of PPID In: Proceedings of the British Equine Veterinary Association Congress, Manchester, UK."},{"key":"10.1016\/j.tvjl.2022.105899_bib20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/avj.12716","article-title":"Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group","volume":"96","author":"Secombe","year":"2018","journal-title":"Australian Veterinary Journal"},{"key":"10.1016\/j.tvjl.2022.105899_bib21","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1111\/jvim.15620","article-title":"Cortisol and adrenocorticotropic hormone concentrations in horses with systemic inflammatory response syndrome","volume":"33","author":"Stewart","year":"2019","journal-title":"Journal of Veterinary Internal Medicine"},{"key":"10.1016\/j.tvjl.2022.105899_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2021.105695","article-title":"Evaluation of the sensitivity and specificity of basal plasma adrenocorticotrophic hormone concentration for diagnosing pituitary pars intermedia dysfunction in horses: a systematic review","volume":"275","author":"Tatum","year":"2021","journal-title":"The Veterinary Journal"},{"key":"10.1016\/j.tvjl.2022.105899_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1136\/inp.h5457","article-title":"Clinical audit in veterinary practice: theory v reality","volume":"37","author":"Waine","year":"2015","journal-title":"In Practice"}],"container-title":["The Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023322001149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090023322001149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:32:35Z","timestamp":1761071555000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090023322001149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":23,"alternative-id":["S1090023322001149"],"URL":"https:\/\/doi.org\/10.1016\/j.tvjl.2022.105899","relation":{},"ISSN":["1090-0233"],"issn-type":[{"value":"1090-0233","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of pituitary pars intermedia dysfunction in practice: A clinical audit","name":"articletitle","label":"Article Title"},{"value":"The Veterinary Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tvjl.2022.105899","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"105899"}}